At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 236 enrolled
Drug / intervention
Mapracorat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dose Ranging Study to Evaluate the Safety and Efficacy of Mapracorat Ophthalmic Formulation, in Subjects With Allergic Conjunctivitis Compared to Vehicle in a Conjunctival Allergen Challenge (CAC).
In Brief
A Phase 2 clinical trial evaluating Mapracorat and Vehicle for Conjunctivitis, Allergic. Completed, enrolled 236 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the dose response, and efficacy of Mapracorat ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs associated with allergic conjunctivitis using a conjunctival allergen challenge (CAC) model.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConjunctivitis, Allergic
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionApr 2011
TodayJul 2026
First PostedFeb 3, 2011
Enrollment StartFeb 1, 2011
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.4 years ago
Interventions
Mapracoratdrug
administered daily to each eye for 2 weeks following allergen challenge using a CAC model
Vehicledrug
administered daily to each eye for 2 weeks following allergen challenge using a CAC model